Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Natural killer group 2 member D (NKG2D) ligands and DNAX accessory molecule 1 (DNAM-1) ligands are a collection of stress-induced cell surface proteins that serve as critical recognition signals for the innate and adaptive immune systems (PMID: 29463950). In humans, NKG2D ligands include MICA, MICB, and the ULBP family (ULBP1-6), while DNAM-1 ligands include CD155 (PVR) and CD112 (Nectin-2) (PMID: 31110339). These ligands are typically absent or expressed at low levels on healthy cells but are significantly upregulated on tumor cells in response to DNA damage, oncogenic transformation, or viral infection (PMID: 28615449). When these ligands bind to their respective activating receptors on natural killer (NK) cells and CD8+ T cells, they trigger potent cytotoxic activity and cytokine production to eliminate the aberrant cells (PMID: 12620224). However, tumors frequently employ evasion strategies such as proteolytic shedding of these ligands to create soluble decoys or upregulating inhibitory receptors like TIGIT to outcompete activating signals (PMID: 12193639, PMID: 19946306). Therapeutic interventions targeting this axis include NKG2D-based CAR-T cells, antibodies designed to prevent ligand shedding, and bispecific molecules that engage these ligands to redirect immune effector cells against the tumor (PMID: 29593067).
Activation of NKG2D and DNAM-1 (CD226) receptors on NK cells and cytotoxic T cells to promote tumor cell lysis and cytokine production (PMID: 28615449).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Natural killer group 2 member D ligands and DNAX accessory molecule 1 ligands (NKG2DLs and DNAM-1Ls).